HLS Therapeutics
VerifiedProvides access to treatments critical to patients and their caregivers with the brand names they trust.
Launch date
Employees
Market cap
-
Net debt
-
Enterprise valuation
$148m (Public information from Jun 2024)
Share price
CAD3.47 HLS.TO
Caledon Ontario (HQ)
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 4 % | 7 % | 2 % | 3 % | 2 % | 15 % | 16 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 39 % | 40 % | 34 % | 35 % | 32 % | 34 % | 37 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (27 %) | (22 %) | (38 %) | (44 %) | (32 %) | (24 %) | (11 %) |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | $0.0 | round |
| N/A | $0.0 | round | |
| N/A | $0.0 | round | |
| N/A | $0.0 | round | |
| investor investor | $0.0 | round | |
| N/A | $0.0 | round | |
* | $91.1m | Post IPO Debt | |
| Total Funding | 000k | ||
Related Content
Recent News about HLS Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.